<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/355g" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/355g/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/355g/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_355g"><akn:num>355g</akn:num><akn:heading>Utilizing real world evidence</akn:heading><akn:content><akn:p>§ 355g. Utilizing real world evidence(a) In generalThe Secretary shall establish a program to evaluate the potential use of real world evidence—(1) to help to support the approval of a new indication for a drug approved under section 355(c) of this title; and

(2) to help to support or satisfy postapproval study requirements.


(b) Real world evidence definedIn this section, the term “real world evidence” means data regarding the usage, or the potential benefits or risks, of a drug derived from sources other than traditional clinical trials.


(c) Program framework(1) In generalNot later than 2 years after December 13, 2016, the Secretary shall establish a draft framework for implementation of the program under this section.


(2) Contents of frameworkThe framework shall include information describing—(A) the sources of real world evidence, including ongoing safety surveillance, observational studies, registries, claims, and patient-centered outcomes research activities;

(B) the gaps in data collection activities;

(C) the standards and methodologies for collection and analysis of real world evidence; and

(D) the priority areas, remaining challenges, and potential pilot opportunities that the program established under this section will address.


(3) Consultation(A) In generalIn developing the program framework under this subsection, the Secretary shall consult with regulated industry, academia, medical professional organizations, representatives of patient advocacy organizations, consumer organizations, disease research foundations, and other interested parties.


(B) ProcessThe consultation under subparagraph (A) may be carried out through approaches such as—(i) a public-private partnership with the entities described in such subparagraph in which the Secretary may participate;

(ii) a contract, grant, or other arrangement, as the Secretary determines appropriate, with such a partnership or an independent research organization; or

(iii) public workshops with th</akn:p></akn:content><akn:subsection eId="subsec_355g_a"><akn:num>(a)</akn:num><akn:heading>In general</akn:heading><akn:content><akn:p>(a) In general The Secretary shall establish a program to evaluate the potential use of real world evidence—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355g_b"><akn:num>(b)</akn:num><akn:heading>Real world evidence defined</akn:heading><akn:content><akn:p>(b) Real world evidence defined In this section, the term “real world evidence” means data regarding the usage, or the potential benefits or risks, of a drug derived from sources other than traditional clinical trials.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355g_c"><akn:num>(c)</akn:num><akn:heading>Program framework</akn:heading><akn:content><akn:p>(c) Program framework</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355g_d"><akn:num>(d)</akn:num><akn:heading>Program implementation</akn:heading><akn:content><akn:p>(d) Program implementation The Secretary shall, not later than 3 years after December 13, 2016, and in accordance with the framework established under subsection (c), implement the program to evaluate the potential use of real world evidence.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355g_e"><akn:num>(e)</akn:num><akn:heading>Guidance for industry</akn:heading><akn:content><akn:p>(e) Guidance for industry The Secretary shall—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355g_f"><akn:num>(f)</akn:num><akn:heading>Rule of construction</akn:heading><akn:content><akn:p>(f) Rule of construction</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>